Literature DB >> 25073467

Bile acid signaling in metabolic disease and drug therapy.

Tiangang Li1, John Y L Chiang2.   

Abstract

Bile acids are the end products of cholesterol catabolism. Hepatic bile acid synthesis accounts for a major fraction of daily cholesterol turnover in humans. Biliary secretion of bile acids generates bile flow and facilitates hepatobiliary secretion of lipids, lipophilic metabolites, and xenobiotics. In the intestine, bile acids are essential for the absorption, transport, and metabolism of dietary fats and lipid-soluble vitamins. Extensive research in the last 2 decades has unveiled new functions of bile acids as signaling molecules and metabolic integrators. The bile acid-activated nuclear receptors farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, vitamin D receptor, and G protein-coupled bile acid receptor play critical roles in the regulation of lipid, glucose, and energy metabolism, inflammation, and drug metabolism and detoxification. Bile acid synthesis exhibits a strong diurnal rhythm, which is entrained by fasting and refeeding as well as nutrient status and plays an important role for maintaining metabolic homeostasis. Recent research revealed an interaction of liver bile acids and gut microbiota in the regulation of liver metabolism. Circadian disturbance and altered gut microbiota contribute to the pathogenesis of liver diseases, inflammatory bowel diseases, nonalcoholic fatty liver disease, diabetes, and obesity. Bile acids and their derivatives are potential therapeutic agents for treating metabolic diseases of the liver.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25073467      PMCID: PMC4180336          DOI: 10.1124/pr.113.008201

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  425 in total

1.  Bile acid is a host factor that regulates the composition of the cecal microbiota in rats.

Authors:  K B M Saiful Islam; Satoru Fukiya; Masahito Hagio; Nobuyuki Fujii; Satoshi Ishizuka; Tadasuke Ooka; Yoshitoshi Ogura; Tetsuya Hayashi; Atsushi Yokota
Journal:  Gastroenterology       Date:  2011-08-10       Impact factor: 22.682

2.  The TGR5 receptor mediates bile acid-induced itch and analgesia.

Authors:  Farzad Alemi; Edwin Kwon; Daniel P Poole; TinaMarie Lieu; Victoria Lyo; Fiore Cattaruzza; Ferda Cevikbas; Martin Steinhoff; Romina Nassini; Serena Materazzi; Raquel Guerrero-Alba; Eduardo Valdez-Morales; Graeme S Cottrell; Kristina Schoonjans; Pierangelo Geppetti; Stephen J Vanner; Nigel W Bunnett; Carlos U Corvera
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

3.  Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression.

Authors:  Masaaki Miyata; Yuki Takamatsu; Hideaki Kuribayashi; Yasushi Yamazoe
Journal:  J Pharmacol Exp Ther       Date:  2009-09-18       Impact factor: 4.030

4.  SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.

Authors:  X Wang; R Sato; M S Brown; X Hua; J L Goldstein
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

5.  Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha.

Authors:  Ji Miao; Sungsoon Fang; Yangjin Bae; Jongsook Kim Kemper
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

6.  Alteration in lipoprotein lipase activity bound to triglyceride-rich lipoproteins in the postprandial state in type 2 diabetes.

Authors:  Valérie Pruneta-Deloche; Agnès Sassolas; Geesje M Dallinga-Thie; François Berthezène; Gabriel Ponsin; Philippe Moulin
Journal:  J Lipid Res       Date:  2004-02-16       Impact factor: 5.922

7.  Expression and function of the bile acid receptor TGR5 in Kupffer cells.

Authors:  Verena Keitel; Markus Donner; Stefanie Winandy; Ralf Kubitz; Dieter Häussinger
Journal:  Biochem Biophys Res Commun       Date:  2008-05-09       Impact factor: 3.575

8.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

9.  Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.

Authors:  Wolfgang Wistuba; Carsten Gnewuch; Gerhard Liebisch; Gerd Schmitz; Thomas Langmann
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

Review 10.  Circadian integration of metabolism and energetics.

Authors:  Joseph Bass; Joseph S Takahashi
Journal:  Science       Date:  2010-12-03       Impact factor: 47.728

View more
  240 in total

Review 1.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 2.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

Review 3.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

4.  G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice.

Authors:  Ajay C Donepudi; Shannon Boehme; Feng Li; John Y L Chiang
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

Review 5.  Cholecystectomy and risk of metabolic syndrome.

Authors:  Agostino Di Ciaula; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Eur J Intern Med       Date:  2018-04-26       Impact factor: 4.487

6.  Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched Akkermansia muciniphila.

Authors:  Lili Sheng; Prasant Kumar Jena; Hui-Xin Liu; Ying Hu; Nidhi Nagar; Denise N Bronner; Matthew L Settles; Andreas J Bäumler; Yu-Jui Yvonne Wan
Journal:  FASEB J       Date:  2018-06-08       Impact factor: 5.191

7.  Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis.

Authors:  Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

8.  Linking Sex Differences in Non-Alcoholic Fatty Liver Disease to Bile Acid Signaling, Gut Microbiota, and High Fat Diet.

Authors:  John Y L Chiang
Journal:  Am J Pathol       Date:  2017-08       Impact factor: 4.307

9.  Nasobiliary drainage prior to surgical biliary diversion in progressive familial intrahepatic cholestasis type II.

Authors:  Giulia Jannone; Xavier Stephenne; Isabelle Scheers; Françoise Smets; Catherine de Magnée; Raymond Reding; Etienne M Sokal
Journal:  Eur J Pediatr       Date:  2020-04-14       Impact factor: 3.183

10.  MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.

Authors:  Young-Chae Kim; Hyunkyung Jung; Sunmi Seok; Yang Zhang; Jian Ma; Tiangang Li; Byron Kemper; Jongsook Kim Kemper
Journal:  Hepatology       Date:  2020-02-14       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.